Three Scientists Building the Case for Longevity as a Business Strategy

The operating-budget argument for longevity science

Healthcare is the fastest-growing cost line in most corporate budgets, and the standard playbook (better plan design, narrower networks, higher deductibles) has delivered diminishing returns. Meanwhile, a different conversation is happening in laboratories and longitudinal studies: what if the root variable is not claims management but biological aging itself?

Three researchers exclusively represented by Stern Strategy Group are building the evidence base for that shift and working with leadership teams to act on it.

Nir Barzilai: turning longevity from a personal aspiration into an organizational strategy

Nir Barzilai directs the Institute for Aging Research at Albert Einstein College of Medicine, where his work on centenarians and the biology of healthy aging has reshaped how the scientific community thinks about lifespan and healthspan. His research focuses on the genetic and metabolic factors that allow some people to live past 100 without the chronic diseases that define late life for most of the population.

Barzilai’s framework starts with a premise that reframes the entire healthcare conversation: aging itself has biological drivers, and those drivers can be studied, measured, and potentially targeted to prevent or delay the diseases that most often limit human potential. Standard medicine treats cancer, cardiovascular disease, Alzheimer’s, and diabetes as separate problems. Barzilai’s work asks what happens if you intervene earlier, at the level of the aging process itself.

For executives, this shifts longevity from a wellness trend to a serious framework for thinking about risk, innovation, workforce resilience, and the future of health. The implications for benefits strategy, workforce planning, and long-term cost modeling are direct. Barzilai works with boards and C-suites on two questions: What does the science now support, and what decisions should a leadership team be making in the next 18 months as the regulatory and clinical landscape shifts?

Eric Verdin: longevity as a leadership issue, not just a healthcare issue

Eric Verdin is President and CEO of the Buck Institute for Research on Aging, the first independent research organization in the United States dedicated solely to understanding the biology of aging and age-related disease. His laboratory work on how metabolism and epigenetic changes drive aging has informed both drug development and behavioral interventions that organizations can implement now.

For executive audiences, Verdin’s central message is both urgent and optimistic: longevity is no longer simply a healthcare issue. It is becoming a leadership issue, a workforce issue, and a business issue. The organizations that understand the implications of longer lives, healthier employees, predictive medicine, and AI-driven healthcare will be better positioned to compete, innovate, and plan for the future.

Verdin’s contribution to the longevity conversation is granularity. He translates mechanisms (how caloric restriction, fasting, exercise, and certain compounds affect cellular aging) into protocols that benefits teams, occupational health leaders, and HR executives can pilot and measure. His work connects the molecular biology to the operational question: What can an organization do today, with current tools, to shift the trajectory of its population’s healthspan?

He speaks to leadership teams about the difference between lifespan and healthspan, why the latter is the variable that matters for workforce strategy, and how to think about investing in interventions that may not show ROI on a two-year budget cycle but fundamentally alter long-term cost and productivity.

Murali Doraiswamy: the future of leadership depends on understanding the future of the mind

Murali Doraiswamy is a professor of psychiatry and medicine at Duke University School of Medicine and a member of the Duke Institute for Brain Sciences. His research spans neuroscience, brain health, digital therapeutics, and the intersection of aging and cognition. He has been a principal investigator on clinical trials for Alzheimer’s disease and related dementias. He has worked extensively on how digital tools and behavioral interventions can preserve cognitive function as populations age.

Doraiswamy offers a practical message: the future of leadership depends on understanding the future of the human mind. He examines how AI will augment human cognition and why organizations that invest in wellbeing, focus, and mental fitness will outperform those that treat brain health as a personal issue rather than a strategic priority. His work on digital cognitive twins and precision psychiatry gives leaders a glimpse into how AI-driven models may soon predict stress, burnout, and cognitive decline before they become organizational problems.

His frameworks help leadership teams separate signal from noise in a market crowded with wellness vendors and longevity startups. He works with executive teams, board health and benefits committees, and chief medical officers on building programs that are evidence-based, measurable, and aligned with the organization’s broader talent and risk strategy. Doraiswamy’s work is particularly relevant for organizations moving from theory to implementation: how to evaluate digital health platforms, how to design benefits that incentivize brain-healthy behaviors, and how to think about cognitive health as a workforce asset rather than a late-stage clinical problem.

The conversation senior leaders should be having

The longevity conversation is moving from the edges of venture capital and biohacking communities into boardrooms and benefits committees. The questions are no longer speculative. They are about resource allocation, pilot design, regulatory positioning, and how to think about workforce health when the science is changing faster than the policy environment.

Barzilai, Verdin, and Doraiswamy bring rigor to that conversation. They ground the discussion in peer-reviewed research, clinical trial data, and the messy realities of translating science into organizational practice. They help leadership teams ask the right questions, identify the decisions that need to be made now, and distinguish between what is actionable today and what is still in development.

Each is exclusively represented by Stern Strategy Group for keynotes, board sessions, and confidential advisory work with leadership teams building longevity and healthspan strategies into workforce planning, benefits design, and long-term cost management. Contact us for a custom proposal.